The effects of Ginger on clinical manifestations and paraclinical features of patients with COVID-19: A randomized double-blind placebo-control clinical trial
Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
Inclusion criteria: Patients with positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging, age ≥18 years, primary clinical symptoms, hospitalization, and signing informed consent.
Exclusion Criteria: Patients with underlying diseases, includingchronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers, use of anticoagulant drugs like warfarin, and hormonal drugs, history of allergy to ginger, and pregnancy and breastfeeding
Inclusion criteria: Patients with positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging, age ≥18 years, primary clinical symptoms, non-hospitalized mild, and signing informed consent.
Exclusion Criteria: Patients with underlying diseases, includingchronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers, use of anticoagulant drugs like warfarin, and hormonal drugs, history of allergy to ginger, and pregnancy and breastfeeding
Inclusion criteria: Patients with positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging, age ≥18 years, primary clinical symptoms, hospitalizationnon-hospitalized mild, and signing informed consent. Exclusion Criteria: Patients with underlying diseases, includingchronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers, use of anticoagulant drugs like warfarin, and hormonal drugs, history of allergy to ginger, and pregnancy and breastfeeding
معیارهای ورود: بیماران با آزمایش مثبت PCR برای COVID-19 و/یا درگیری ریه در تصویربرداری، سن <18 سالگی، علائم بالینی اولیه، بستری در بیمارستان و امضای رضایت آگاهانه.
معیارهای خروج از مطالعه: بیماران مبتلا به بیماری های زمینه ای از جمله هپاتیت مزمن، سیروز کبدی، بیماری های کبدی کلستاتیک، التهاب کیسه صفرا و زخم های گوارشی، استفاده از داروهای ضد انعقادی مانند وارفارین، و داروهای هورمونی، سابقه ای از حساسیت به زنجبیل و خانم ها در دوران بارداری و شیردهی.
معیارهای ورود: بیماران با آزمایش مثبت PCR برای COVID-19 و/یا درگیری ریه در تصویربرداری، سن <18 سالگی، علائم بالینی اولیه، با شدت خفیف و سرپایی و امضای رضایت آگاهانه.
معیارهای خروج از مطالعه: بیماران مبتلا به بیماری های زمینه ای از جمله هپاتیت مزمن، سیروز کبدی، بیماری های کبدی کلستاتیک، التهاب کیسه صفرا و زخم های گوارشی، استفاده از داروهای ضد انعقادی مانند وارفارین، و داروهای هورمونی، سابقه ای از حساسیت به زنجبیل و خانم ها در دوران بارداری و شیردهی.
معیارهای ورود: بیماران با آزمایش مثبت PCR برای COVID-19 و/یا درگیری ریه در تصویربرداری، سن <18 سالگی، علائم بالینی اولیه، بستری در بیمارستانبا شدت خفیف و سرپایی و امضای رضایت آگاهانه. معیارهای خروج از مطالعه: بیماران مبتلا به بیماری های زمینه ای از جمله هپاتیت مزمن، سیروز کبدی، بیماری های کبدی کلستاتیک، التهاب کیسه صفرا و زخم های گوارشی، استفاده از داروهای ضد انعقادی مانند وارفارین، و داروهای هورمونی، سابقه ای از حساسیت به زنجبیل و خانم ها در دوران بارداری و شیردهی.
Group A will be patients receiving standard treatment of COVID-19 according to the Ministry of Health's protocol. Group B will be patients receiving, in addition to the standard treatment, a ginger-based herbal tablet, at a dose of 1000 mg three times a day for a period of 14 days.
Group A will be patients receiving standard treatment of COVID-19 according to the Ministry of Health's protocol. Group B will be patients receiving, in addition to the standard treatment, a ginger-based herbal tablet, at a dose of 1000 mg three times a day for a period of seven days.
Group A will be patients receiving standard treatment of COVID-19 according to the Ministry of Health's protocol. Group B will be patients receiving, in addition to the standard treatment, a ginger-based herbal tablet, at a dose of 1000 mg three times a day for a period of 14seven days.
گروه A بيماران تحت درمان استاندارد بیماری COVID-19 (پرتکل وزارت بهداشت، درمان و آموزش پزشکی) خواهند گرفت. گروه B بیمارانی هستند که علاوه بر درمان استاندارد، یک قرص گیاهی مبتنی بر زنجبیل، با دوز 1000 میلی گرم سه بار در روز به مدت 14 روز دریافت می کنند.
گروه A بيماران تحت درمان استاندارد بیماری COVID-19 (پرتکل وزارت بهداشت، درمان و آموزش پزشکی) خواهند گرفت. گروه B بیمارانی هستند که علاوه بر درمان استاندارد، یک قرص گیاهی مبتنی بر زنجبیل، با دوز 1000 میلی گرم سه بار در روز به مدت هفت روز دریافت می کنند.
گروه A بيماران تحت درمان استاندارد بیماری COVID-19 (پرتکل وزارت بهداشت، درمان و آموزش پزشکی) خواهند گرفت. گروه B بیمارانی هستند که علاوه بر درمان استاندارد، یک قرص گیاهی مبتنی بر زنجبیل، با دوز 1000 میلی گرم سه بار در روز به مدت 14هفت روز دریافت می کنند.
Checking the fever, respiratory rate, Oxygen saturation
Evaluation of white blood cell count, C-reactive protein
Occurrence of adverse drug reactions
Checking the SARS-CoV-2 clearance, improvement of fever
Evaluation of white blood cell count
Requremet for hospital admission
Occurrence of adverse drug reactions
Checking the feverSARS-CoV-2 clearance, respiratory rate, Oxygen saturationimprovement of fever Evaluation of white blood cell count, C-reactive protein Requremet for hospital admission Occurrence of adverse drug reactions
بررسی تب، فرکانس تنفس، میزان اشباع اكسيژن خون
بررسی تعداد گلبولهای سفید، C-RP
بروز عوارض جانبی دارویی
بررسی کلیرانس ویروس، بهبود تب
بررسی تعداد گلبولهای سفید
میزان نیاز به بررسی در بیمارستان
بروز عوارض جانبی دارویی
بررسی تبکلیرانس ویروس، فرکانس تنفس، میزان اشباع اكسيژن خونبهبود تب بررسی تعداد گلبولهای سفید، C-RP میزان نیاز به بررسی در بیمارستان بروز عوارض جانبی دارویی
General information
2020-05-21, 1399/03/01
2020-11-21, 1399/09/01
2020-0511-21 00:00:00
2020-08-22, 1399/06/01
2021-02-19, 1399/12/01
20202021-0802-2219 00:00:00
empty
Moderate patients take many antivirals and other drugs that might interact with Ginger preparations. Moreover, the process of patient recruitment was very slow considering eligibility criteria.
Hence, the protocol of the trial updated in eligibility criteria, intervention, and outcomes for outpatients with Covid-19.
This trial was also conducted on outpatients (mild) with COVID-19, instead of inpatients (moderate).
Moderate patients take many antivirals and other drugs that might interact with Ginger preparations. Moreover, the process of patient recruitment was very slow considering eligibility criteria. Hence, the protocol of the trial updated in eligibility criteria, intervention, and outcomes for outpatients with Covid-19. This trial was also conducted on outpatients (mild) with COVID-19, instead of inpatients (moderate).
empty
بیماران معتدل بسیاری از داروهای ضد ویروسی و داروهای دیگری را مصرف می کنند که ممکن است با داروهای زنجبیل تداخل داشته باشند. علاوه بر این ، روند جذب بیماران با توجه به معیارهای واجد شرایط بودن بسیار کند بود.
از این رو ، پروتکل این آزمایش در معیارهای واجد شرایط بودن ، مداخله و نتایج بیماران سرپایی مبتلا به کووید -19 به روز شد.
این کارآزمایی همچنین بر روی بیماران سرپایی (خفیف) مبتلا به COVID-19 به جای بیماران بستری (متوسط) انجام شد.
بیماران معتدل بسیاری از داروهای ضد ویروسی و داروهای دیگری را مصرف می کنند که ممکن است با داروهای زنجبیل تداخل داشته باشند. علاوه بر این ، روند جذب بیماران با توجه به معیارهای واجد شرایط بودن بسیار کند بود. از این رو ، پروتکل این آزمایش در معیارهای واجد شرایط بودن ، مداخله و نتایج بیماران سرپایی مبتلا به کووید -19 به روز شد. این کارآزمایی همچنین بر روی بیماران سرپایی (خفیف) مبتلا به COVID-19 به جای بیماران بستری (متوسط) انجام شد.
Primary outcomes
#1
Body temperature
SARS-CoV-2 clearance
Body temperatureSARS-CoV-2 clearance
دمای بدن
بررسی کلیرانس ویروس
دمای بدنبررسی کلیرانس ویروس
Before intervention and daily during the study
Before intervention and day 7
Before intervention and daily during the studyday 7
قبل از مداخله و هر روز در طی مطالعه
قبل از مداخله و روز هفتم مطالعه
قبل از مداخله و هر روز در طیهفتم مطالعه
Thermometer
PCR test
ThermometerPCR test
دماسنج
تست PCR
دماسنجتست PCR
#2
Respiratory rate
fever
Respiratory ratefever
فرکانس تنفس
تب
فرکانس تنفستب
Respiratory Count
Thermometer
Respiratory CountThermometer
شمارش تنفس
دماسنج
شمارش تنفسدماسنج
#3
Oxygen saturation
White blood cell count
Oxygen saturationWhite blood cell count
میزان اشباع اکسیژن
تعداد گلبول های سفید خون
میزان اشباع اکسیژنتعداد گلبول های سفید خون
Before intervention and daily during the study
Before intervention and day 7
Before intervention and daily during the studyday 7
قبل از مداخله و هر روز در طی مطالعه
قبل از مداخله و روز هفتم پس از مداخله
قبل از مداخله و هر روز در طی مطالعههفتم پس از مداخله
Pulse oximeter
Labratory
Pulse oximeterLabratory
پالس اکسی متر
آزمایشگاهی
پالس اکسی مترآزمایشگاهی
Secondary outcomes
#1
Lymphocytopenia
Hospital admission
LymphocytopeniaHospital admission
لنفوسیتوپنی
بستری در بیمارستان
لنفوسیتوپنیبستری در بیمارستان
Before intervention and days 7 and 14 after the intervention
During the intervention
Before intervention and days 7 and 14 afterDuring the intervention
قبل از مداخله و روزهای 7 و 14 بعد از شروع مداخله
در طی مداخله
قبل ازدر طی مداخله و روزهای 7 و 14 بعد از شروع مداخله
Cell count
Questionnaire
Cell countQuestionnaire
شمارش سلولی
پرسشنامه
شمارش سلولیپرسشنامه
#2
C-reactive protein
Incidence of serious adverse events
C-reactive proteinIncidence of serious adverse events
پروتئین واکنشی C
بروز عوارض ناخواسته جدی
پروتئین واکنشی Cبروز عوارض ناخواسته جدی
Before intervention and days 7 and 14 after the intervention
Before intervention and daily during the study
Before intervention and days 7 and 14 afterdaily during the interventionstudy
قبل از مداخله و روزهای 7 و 14 بعد از شروع مداخ
قبل از مداخله و هر روز در طی مطالعه
قبل از مداخله و روزهای 7 و 14 بعد از شروع مداخهر روز در طی مطالعه
C-RP kit
Questionnaire
C-RP kitQuestionnaire
کیت C-RP
پرسشنامه
کیت C-RPپرسشنامه
#3
Incidence of serious adverse events
empty
Incidence of serious adverse events
بروز عوارض ناخواسته جدی
empty
بروز عوارض ناخواسته جدی
Before intervention and daily during the study
empty
Before intervention and daily during the study
قبل از مداخله و هر روز در طی مطالعه
empty
قبل از مداخله و هر روز در طی مطالعه
Questionnaire
empty
Questionnaire
پرسشنامه
empty
پرسشنامه
Intervention groups
#1
Intervention group: The standard treatment regimen for COVID-19 along with a Ginger-based herbal medicine (Vomigone 500 mg tablets, registration number: 9406633051781240, Dineh Iran Pharmaceutical Company) at a dose of 1000 mg three times a day for a period of 14 days
Intervention group: The standard treatment regimen for COVID-19 along with a Ginger-based herbal medicine (Vomigone 500 mg tablets, registration number: 9406633051781240, Dineh Iran Pharmaceutical Company) at a dose of 1000 mg three times a day for a period of seven days
Intervention group: The standard treatment regimen for COVID-19 along with a Ginger-based herbal medicine (Vomigone 500 mg tablets, registration number: 9406633051781240, Dineh Iran Pharmaceutical Company) at a dose of 1000 mg three times a day for a period of 14seven days
گروه مداخله: رژیم درمانی استاندارد COVID-19 به همراه داروی گیاهی مبتنی بر زنجبیل (قرص ومیگان 500 میلی گرم، شماره ثبت: 9406633051781240، شرکت دارویی دینه ایران) با دوز 1000میلی گرم سه بار در روز به مدت 14 روز
گروه مداخله: رژیم درمانی استاندارد COVID-19 به همراه داروی گیاهی مبتنی بر زنجبیل (قرص ومیگان 500 میلی گرم، شماره ثبت: 9406633051781240، شرکت دارویی دینه ایران) با دوز 1000میلی گرم سه بار در روز به مدت 7 روز
گروه مداخله: رژیم درمانی استاندارد COVID-19 به همراه داروی گیاهی مبتنی بر زنجبیل (قرص ومیگان 500 میلی گرم، شماره ثبت: 9406633051781240، شرکت دارویی دینه ایران) با دوز 1000میلی گرم سه بار در روز به مدت 147 روز
#2
Control group: The standard treatment for COVID-19 based on the Ministry of Health's protocol including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 200 mg twice a day for a period of 14 days, along with a Vomigone-liked placebo tablets (Dineh Iran Pharmaceutical Company) at a dose of two tablets three times a day for a period of 14 days
Control group: The standard treatment for COVID-19 based on the Ministry of Health's protocol including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 200 mg twice a day for a period of seven days, along with a Vomigone-liked placebo tablets (Dineh Iran Pharmaceutical Company) at a dose of two tablets three times a day for a period of seven days
Control group: The standard treatment for COVID-19 based on the Ministry of Health's protocol including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 200 mg twice a day for a period of 14seven days, along with a Vomigone-liked placebo tablets (Dineh Iran Pharmaceutical Company) at a dose of two tablets three times a day for a period of 14seven days
گروه کنترل: درمان استاندارد برای COVID-19 براساس پروتکل وزارت بهداشت شامل هیدروکسی کلروکین سولفات (شرکت داروسازی امین، اصفهان) با دوز 200 میلی گرم دو بار در روز به مدت 14 روز به همراه قرص های دارونما شبیه ومیگان (شرکت داروسازی دینه ایران) با دوز دو قرص سه بار در روز به مدت 14 روز
گروه کنترل: درمان استاندارد برای COVID-19 براساس پروتکل وزارت بهداشت شامل هیدروکسی کلروکین سولفات (شرکت داروسازی امین، اصفهان) با دوز 200 میلی گرم دو بار در روز به مدت هفت روز به همراه قرص های دارونما شبیه ومیگان (شرکت داروسازی دینه ایران) با دوز دو قرص سه بار در روز به مدت 7 روز
گروه کنترل: درمان استاندارد برای COVID-19 براساس پروتکل وزارت بهداشت شامل هیدروکسی کلروکین سولفات (شرکت داروسازی امین، اصفهان) با دوز 200 میلی گرم دو بار در روز به مدت 14هفت روز به همراه قرص های دارونما شبیه ومیگان (شرکت داروسازی دینه ایران) با دوز دو قرص سه بار در روز به مدت 147 روز
Protocol summary
Study aim
Evaluation of the effects of Ginger on clinical symptoms and laboratory signs in patients with COVID-19
Design
A phase 3, Placebo-controlled, Paralleled, double-blind, randomized clinical trial, 84 patients, randomized using blocks
Settings and conduct
This study will be conducted at the Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas.The study population is 84 patients with COVID-19 (42 patients in control group and 42 in study group).
Participants/Inclusion and exclusion criteria
Inclusion criteria: Patients with positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging, age ≥18 years, primary clinical symptoms, non-hospitalized mild, and signing informed consent.
Exclusion Criteria: Patients with underlying diseases, includingchronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers, use of anticoagulant drugs like warfarin, and hormonal drugs, history of allergy to ginger, and pregnancy and breastfeeding
Intervention groups
Group A will be patients receiving standard treatment of COVID-19 according to the Ministry of Health's protocol. Group B will be patients receiving, in addition to the standard treatment, a ginger-based herbal tablet, at a dose of 1000 mg three times a day for a period of seven days.
Main outcome variables
Checking the SARS-CoV-2 clearance, improvement of fever
Evaluation of white blood cell count
Requremet for hospital admission
Occurrence of adverse drug reactions
General information
Reason for update
Moderate patients take many antivirals and other drugs that might interact with Ginger preparations. Moreover, the process of patient recruitment was very slow considering eligibility criteria.
Hence, the protocol of the trial updated in eligibility criteria, intervention, and outcomes for outpatients with Covid-19.
This trial was also conducted on outpatients (mild) with COVID-19, instead of inpatients (moderate).
Acronym
IRCT registration information
IRCT registration number:IRCT20200506047323N1
Registration date:2020-05-23, 1399/03/03
Registration timing:prospective
Last update:2021-10-29, 1400/08/07
Update count:1
Registration date
2020-05-23, 1399/03/03
Registrant information
Name
Mohammad Fathalipour
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 76 3371 0406
Email address
m.fathalipour@hums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-11-21, 1399/09/01
Expected recruitment end date
2021-02-19, 1399/12/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The effects of Ginger on clinical manifestations and paraclinical features of patients with COVID-19: A randomized double-blind placebo-control clinical trial
Public title
The effects of Ginger in treatment COVID-19
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Age ≥18 years
Positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging
Primary clinical symptoms
Hospitalized
Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm
Exclusion criteria:
Underlying diseases, including chronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers
Use of anticoagulant drugs like warfarin, and hormonal drugs
History of allergy to ginger
Pregnancy and breastfeeding
Age
From 18 years old
Gender
Both
Phase
3
Groups that have been masked
Participant
Care provider
Data and Safety Monitoring Board
Sample size
Target sample size:
84
Randomization (investigator's opinion)
Randomized
Randomization description
Block randomization will be performed (each block consists 6 patients). Allocation sequence and concealment codes will be generated using www.sealedenvelope.com. The closed envelope method will be used to hide the allocation sequence.
Blinding (investigator's opinion)
Double blinded
Blinding description
The medication and placebo will be coded by the project manager. Patients will be randomly allocated within the blocks based on the hidden codes, and study participants, physicians, and nurses who evaluate the outcomes will be blind to the intervention and studied groups.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Hormozgan University of Medical Sciences
Street address
Jomhuri Eslami Blvd
City
Bandar Abbas
Province
Hormozgan
Postal code
7919915519
Approval date
2020-05-20, 1399/02/31
Ethics committee reference number
IR.HUMS.REC.1399.130
Health conditions studied
1
Description of health condition studied
COVID-19 disease
ICD-10 code
U07.2
ICD-10 code description
COVID-19, virus not identified
Primary outcomes
1
Description
SARS-CoV-2 clearance
Timepoint
Before intervention and day 7
Method of measurement
PCR test
2
Description
fever
Timepoint
Before intervention and daily during the study
Method of measurement
Thermometer
3
Description
White blood cell count
Timepoint
Before intervention and day 7
Method of measurement
Labratory
Secondary outcomes
1
Description
Hospital admission
Timepoint
During the intervention
Method of measurement
Questionnaire
2
Description
Incidence of serious adverse events
Timepoint
Before intervention and daily during the study
Method of measurement
Questionnaire
Intervention groups
1
Description
Intervention group: The standard treatment regimen for COVID-19 along with a Ginger-based herbal medicine (Vomigone 500 mg tablets, registration number: 9406633051781240, Dineh Iran Pharmaceutical Company) at a dose of 1000 mg three times a day for a period of seven days
Category
Treatment - Drugs
2
Description
Control group: The standard treatment for COVID-19 based on the Ministry of Health's protocol including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 200 mg twice a day for a period of seven days, along with a Vomigone-liked placebo tablets (Dineh Iran Pharmaceutical Company) at a dose of two tablets three times a day for a period of seven days
Category
Treatment - Drugs
Recruitment centers
1
Recruitment center
Name of recruitment center
Shahid Mohammadi Hospital
Full name of responsible person
Parivash Davoodian
Street address
Jomhuri Eslami Blvd
City
Bandar Abbas
Province
Hormozgan
Postal code
7919915519
Phone
+98 76 3334 7000
Fax
+98 76 3334 5003
Email
shmh@hums.ac.ir
Web page address
http://shmh.hums.ac.ir/
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Bandare-abbas University of Medical Sciences
Full name of responsible person
Teamur Aghamolaei
Street address
Jomhuri Eslami Blvd
City
Bandar Abbas
Province
Hormozgan
Postal code
7919915519
Phone
+98 76 3333 3280
Fax
+98 76 3334 6994
Email
mail@hums.ac.ir
Web page address
http://hums.ac.ir/
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Hormozgan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Bandare-abbas University of Medical Sciences
Full name of responsible person
Mohammad Fathalipour
Position
Consultant
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Emam Hossein Blvd
City
Bandar Abbas
Province
Hormozgan
Postal code
7919691982
Phone
+98 76 3371 0406
Fax
+98 76 3371 0389
Email
m.fathalipour@hums.ac.ir
Web page address
https://pharf.hums.ac.ir/
Person responsible for scientific inquiries
Contact
Name of organization / entity
Bandare-abbas University of Medical Sciences
Full name of responsible person
Parivash Davoodian
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Infectious diseases
Street address
Jomhuri Eslami Blvd
City
Bandar Abbas
Province
Hormozgan
Postal code
7919915519
Phone
+98 76 3333 3280
Email
parivash.davoodian@hums.ac.ir
Person responsible for updating data
Contact
Name of organization / entity
Bandare-abbas University of Medical Sciences
Full name of responsible person
Mohammad Fathalipour
Position
Consultant
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Emam Hossein Blvd
City
Bandar Abbas
Province
Hormozgan
Postal code
07633710389
Phone
+98 76 3371 0406
Fax
+98 76 3371 0389
Email
m.fathalipour@hums.ac.ir
Web page address
https://pharf.hums.ac.ir/
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
Information regarding the study outcomes will be shared.
When the data will become available and for how long
Data will become available after publication of obtained results
To whom data/document is available
Only academic institutions
Under which criteria data/document could be used
The study protocol or proposal should be approved by Ethics committee of institutions. The rights of authors and sponsors should be respected.
From where data/document is obtainable
M.fathalipour@yahoo.com
M.fathalipour@hums.ac.ir
What processes are involved for a request to access data/document
Requests should be addressed to the Technology and Research Vice-chancellery of Hormozgan University of Medical Sciences and the project executor should informed.